Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
7 cost-effectiveness analyses and 4 studies reporting utility weights · 7 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 7 |
| Studies reporting utility weights | 4 |
Cost-effectiveness analyses
Analyses of Tovorafenib (DAY101 and TAK-580)
No evidence found.
Treatments for the same indication
Molecular testing for BRAF fusion at diagnosis versus no testing in newly diagnosed pediatric low-grade glioma, Canada: Rios et al. (2022)
Relevance: Evaluates molecular testing for BRAF fusion at diagnosis against no testing in newly diagnosed pediatric low-grade glioma in Canada, the testing step that identifies the RAF-altered population eligible for LOGGIC/FIREFLY-2 and that section 2 describes as a Canadian microsimulation.
“We performed a model-based cost-utility analysis comparing two strategies: molecular testing to determine BRAF fusion status at diagnosis against no molecular testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We developed a microsimulation to model the lifetime health and cost outcomes (in quality-adjusted life years (QALYs) and 2018 CAD, respectively) for a simulated cohort of 100,000 patients newly diagnosed with PLGG after their initial surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost and health outcomes were discounted at a rate of 1.5% as recommended by national guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We assigned costs from the perspective of a Canadian public healthcare payer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When no radiation benefit was assumed, patients who received molecular testing at diagnosis experienced a gain in life expectancy of 1.07 (95% CI, 0;2.39) years, 0.38 (0.08;0.77) more QALYs, and a $1384 ($-1204; $3486) reduction in total costs compared to patients who did not receive molecular testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even under the assumption of radiation benefit to survival, the testing strategy remained dominant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
The same disease in other populations or settings
Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy alone in high-risk low-grade glioma, United States: Qian et al. (2017)
Relevance: Evaluates radiotherapy with procarbazine, lomustine, and vincristine against radiotherapy alone in high-risk low-grade glioma from a United States health care perspective, with stable and progressive health states.
“The health states were: stable, progressive, and dead (Fig. 1B). Patients were followed monthly over their remaining lifetimes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Economic analysis was conducted from the health care perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, we applied an annual discounting rate of 3% to all costs and benefits incurred in the future to adjust for inflation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From time of RT initiation, patients treated with RT lived 5.17 QALYs at a cumulative cost of $139598, and those treated with RT+PCV lived 9.94 QALYs at a cumulative cost of $188232. The addition of PCV to RT resulted in an additional 11.82 life-years and 4.77 QALYs. Gains were achieved at an incremental cost of $48635. Taken together, the ICER of the addition of PCV to RT was $10186 per QALY gained” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic sensitivity analysis performed with 10000 Monte Carlo simulations showed a 99.96% chance of cost-effectiveness at a willingness-to-pay (WTP) threshold of $100000 per QALY gained” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Related diseases and analogous treatments
Proton therapy versus photon therapy in pediatric medulloblastoma, United States: Mailhot Vega et al. (2013)
Relevance: Evaluates proton against photon therapy for pediatric medulloblastoma from a United States societal perspective, modeling late adverse events in survivors, a form of the radiotherapy that section 2 lists for pediatric low-grade glioma.
“A cost-effective analysis was performed from the societal perspective using a Monte Carlo simulation model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A population of pediatric medulloblastoma survivors aged 18 years was studied who had received treatment at age 5 years and who were at risk of developing 10 adverse events, such as growth hormone deficiency, coronary artery disease, ototoxicity, secondary malignant neoplasm, and death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results from the base case demonstrated that proton therapy was associated with higher quality-adjusted life years and lower costs; therefore, it dominated photon therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic sensitivity analysis illustrated the domination of proton therapy over photon therapy in 96.4% of simulations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab with temozolomide and irinotecan versus temozolomide and irinotecan in recurrent pediatric medulloblastoma, China: Chen et al. (2022)
Relevance: Evaluates bevacizumab added to temozolomide and irinotecan against temozolomide and irinotecan in recurrent pediatric medulloblastoma from a Chinese societal perspective, a model of systemic therapy for a pediatric central nervous system tumor.
“Patients enter the Markov model in a stable disease state, and then they may remain in a stable disease state (event-free survival, EFS) or experience toxic effects, disease progression (PD), or death” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the survival and follow-up time, we set the model period to be 1 month.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time horizon chosen for this model is 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs are estimated from the perspective of Chinese society” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the cost and utility values were discounted at an annual discount rate of 3%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our base case analysis showed that the total costs of treatment increased from $8,786.403 to $27,603.420 with the combination bevacizumab vs. the two-agent chemotherapy regimen. Treatment with T+I+B combination therapy was associated with an increase in effectiveness of 0.280 QALYs from 0.867 to 1.147 QALYs T+I regimen. The incremental cost-effectiveness ratio was $67,203.632/QALY, which exceeded our pre-specified willingness-to-pay threshold ($38,136.26/QALY)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“probabilistic sensitivity analysis (1,000 iterations) demonstrated that the ICER was consistently greater than $38,136.26/QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line dabrafenib plus trametinib versus vemurafenib in BRAF V600 mutation-positive unresectable or metastatic melanoma, China: Gao et al. (2021)
Relevance: Evaluates first-line dabrafenib plus trametinib, the RAF and MEK inhibitor combination that section 2 describes as first-line therapy for BRAF V600 pediatric low-grade glioma, against vemurafenib in BRAF V600-mutant metastatic melanoma in China.
“This study employed a partitioned survival model with three health states (progression-free survival, post-progression survival and dead) to parameterize the data derived from Combi-v trial and extrapolated to 30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time horizon was 30 years, starting from patients entering the model. This analysis was conducted from a Chinese healthcare system perspective; thus, only direct healthcare costs related to treatment of metastatic melanoma were considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base case analysis, both cost and effectiveness were discounted at a rate of 5% per year, as recommended by the China guidelines for pharmacoeconomic evaluations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cost parameters were converted to 2020 United States dollars (1 dollar = 6.52 Chinese yuan).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination group obtained 1.09 more QALYs than vemurafenib (2.48 QALYs vs. 1.39 QALYs). Total life-time costs were $119,766 and $115,933 in the D + T group and vemurafenib group, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ICER for D + T versus vemurafenib was $3511 per QALY gained” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cost-effectiveness acceptability curve for D + T versus vemurafenib shows that when the willingness-to-pay is $33,357 per QALY (three times the GDP per capita in China in 2020), the probability of D + T being cost-effective is 90%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjuvant dabrafenib plus trametinib versus no treatment and pembrolizumab in resected BRAF-mutant stage III melanoma, United States Medicare: Mojtahed et al. (2021)
Relevance: Evaluates adjuvant dabrafenib-based therapy against no treatment and against pembrolizumab in resected BRAF-mutant stage III melanoma among Medicare beneficiaries in the United States.
“In this cost-effectiveness analysis, a Markov microsimulation model was used to simulate the healthcare trajectory of patients randomized to receive either first-line targeted therapy (dabrafenib-trametinib) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The base case was a 65-year-old Medicare patient with BRAF V600E-mutant resected stage III melanoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dabrafenib-trametinib provided 1.83 QALYs over no treatment and 0.23 QALYs over the most effective immunotherapy, pembrolizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dabrafenib-trametinib was associated with an ICER of $95,758/QALY over no treatment and $285,863/QALY over pembrolizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab yielded an ICER of $68,396/QALY over no treatment and dominated other immunotherapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Encorafenib with binimetinib versus dabrafenib with trametinib and vemurafenib with cobimetinib in BRAF V600-mutant unresectable or metastatic melanoma, France: Trouiller et al. (2024)
Relevance: Evaluates encorafenib with binimetinib against dabrafenib with trametinib and vemurafenib with cobimetinib in BRAF V600-mutant unresectable or metastatic melanoma from the French payer perspective, a comparison that includes the dabrafenib with trametinib combination section 2 describes for BRAF V600 pediatric low-grade glioma.
“The objective of this study was to determine the cost-effectiveness of encorafenib with binimetinib (EncoBini) as compared to other targeted double combination therapies, namely dabrafenib with trametinib (DabraTrame) and vemurafenib with cobimetinib (VemuCobi), for the treatment of BRAF V600-mutant unresectable or metastatic melanoma (MM) from the French payer perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A partitioned survival model was developed considering a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over a lifetime horizon, EncoBini was associated, on average, with reduced costs and increased quality adjusted life years (QALYs), dominating both targeted double combination therapies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For a willingness-to-pay threshold of €90,000 per QALY, the probability of EncoBini being cost-effective against either comparator remained above 80%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights
Utility weights from analyses of Tovorafenib (DAY101 and TAK-580)
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
Utility weights for stable and progressive states and major toxicity of treatment, low-grade glioma: Qian et al. (2017)
Relevance: Utilities based on HUI2 scores for stable and progressive low-grade glioma, with a decrement for major toxicity of treatment modeled on hematologic toxicity.
“based on HUI2 HRQL scores” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“decrease of 0.02 QALY per consecutive month of progression (maximum 30 cumulative decreases)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“utility decrement modeled hematologic toxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for related diseases and analogous treatments
Utility weights for late effects of cranial radiotherapy in childhood, pediatric medulloblastoma survivors: Mailhot Vega et al. (2013)
Relevance: Utilities for late effects of cranial radiotherapy in childhood, such as growth hormone deficiency, coronary artery disease, ototoxicity, and secondary malignant neoplasm, in survivors of pediatric medulloblastoma.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Utility weights for event-free survival and progressed disease, recurrent pediatric medulloblastoma: Chen et al. (2022)
Relevance: Utilities for event-free survival and progressed disease in a pediatric central nervous system tumor treated with systemic therapy.
“Since basic information on utility value was not mentioned in the original literature, health utility value was referred to in published studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Utility values for event-free survival, disease progression, and death status were 0.89, 0.73, and 0.00, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights for progression-free and post-progression states on dabrafenib plus trametinib and on vemurafenib, BRAF V600 mutation-positive metastatic melanoma: Gao et al. (2021)
Relevance: EQ-5D utilities for progression-free and post-progression states on dabrafenib plus trametinib and on vemurafenib in BRAF V600-mutant melanoma.
“Health state utility values were estimated based on the EuroQol-5D-3L (EQ-5D-3L) data reported from the two treatment arms in the Combi-v trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, PFS utilities of 0.823 and 0.688 were assigned to patients receiving combination therapy and vemurafenib, respectively; PPS utilities of 0.811 and 0.665 for combination therapy and vemurafenib, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Ratios | tovorafenib OR "DAY101" OR "TAK-580" OR Ojemda | 0 |
| Ratios | "low-grade glioma" OR "low grade glioma" | 3 |
| Ratios | dabrafenib AND trametinib | 50 |
| Ratios | (glioma OR "brain tumor") AND (pediatric OR children OR paediatric) | 8 |
| Ratios | selumetinib OR "neurofibromatosis" | 0 |
| Ratios | vinblastine OR (carboplatin AND vincristine) | 41 |
| Ratios | "proton" AND (medulloblastoma OR pediatric OR children OR childhood) | 7 |
| Weights | "low-grade glioma" OR "low grade glioma" OR "pediatric brain tumor" OR "childhood brain tumor" | 3 |
| Weights | ("visual impairment" OR "vision loss" OR blindness) AND (children OR pediatric OR childhood) | 33 |
| Methods | tovorafenib OR "low-grade glioma" OR "low grade glioma" OR "pilocytic astrocytoma" | 2 |